Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin

Figure 2 Shortening of mean telomere length (terminal restriction fragments, TRF) in DOX treated BEL-7404 human hepatoma cells. Lane 1 and 18, molecular marker; Lane 17, cell control; Lane 2-6, DOX treated for 72 h (2.5, 1.25, 0.625, 0.313 and 0.156 μM); Lane 7-11: DOX treated for 48 h (2.5, 1.25, 0.625, 0.313 and 0.156 μM); Lane 12-16: DOX treated for 24 h (2.5, 1.25, 0.625, 0.313 and 0.156 μM).